A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Wang, Ting
Huang, Lu Li Lin
Liu, Jie Wei
Zhu, Da Xing
Dong, Jing Si
Deng, Han Yu
Zheng, Xi
Tian, Long
Jiang, Li Li
Wang, Wei Ya
Zhou, Ping
Su, Ming Gang
Pu, Dan
Cai, Xu Yu
Feng, Ming Yang
Ou, Xue Jin
Wang, Yongsheng
Zhou, Qing Hua
机构：
[1] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Nucl Med, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Ctr Canc, Thorac Oncol Ward, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8024
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant chemotherapy for resectable non-small cell lung cancer
    Finkelstein, EI
    Urschel, JD
    Takita, H
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1997, 16 (04) : 437 - 439
  • [22] Neoadjuvant Combination Sintilimab plus Chemotherapy in Patients with Resectable Stage IIIA Non-Small Cell Lung Cancer.
    Ma, K.
    Sun, C.
    Jia, X.
    Wang, X.
    Xu, Y.
    Guo, Y.
    Qiu, S.
    Shao, G.
    Zhang, P.
    Liu, Y.
    Ma, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S650
  • [23] Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer
    Zhang, Y.
    Zeng, L.
    Zhang, X.
    Zhou, Y.
    Zhang, B.
    Jiang, W.
    Yang, N.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1014 - S1015
  • [24] A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer
    Granetzny, A
    Striehn, E
    Bosse, U
    Wagner, W
    Koch, O
    Vogt, U
    Froeschle, P
    Klinke, F
    ANNALS OF THORACIC SURGERY, 2003, 75 (04): : 1107 - 1112
  • [25] Management of stage IIIA non-small cell lung cancer (NSCLC) role of the chemotherapy
    Baudoux, Nathalie
    Friedlaender, Alex
    Addeo, Alfredo
    CURRENT CHALLENGES IN THORACIC SURGERY, 2022, 4
  • [26] A phase II feasibility study of preoperative chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer.
    Miyata, Yoshihiro
    Tsutani, Yasuhiro
    Suzuki, Kenji
    Takamochi, Kazuya
    Tanaka, Fumihiro
    Nakayama, Haruhiko
    Yamashita, Yoshinori
    Tsuboi, Masahiro
    Oda, Makoto
    Okada, Morihito
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] A phase II randomised study of gemcitabine-cisplatin (GP) vs mitomycin-ifosfamide-cisplatin (MIP) as neoadjuvant chemotherapy in resectable stage IIIA non-small cell lung cancer (NSCLC)
    Brechot, J
    Saintigny, R
    Azorin, J
    Valeyre, D
    Breau, J
    Morere, J
    LUNG CANCER, 2005, 49 : S92 - S92
  • [28] Is the combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA non small cell lung cancer (NSCLC) feasible?
    Kolek, Vitezslav
    Grygarkova, I.
    Cwiertka, K.
    Hajduch, M.
    Klein, J.
    Neoral, C.
    ANNALS OF ONCOLOGY, 2006, 17 : 223 - 224
  • [29] Stage IIIA non-small cell lung carcinoma (NSCLC): Treatment choices following neoadjuvant chemotherapy
    Kappers, I
    van Zandwijk, N
    Burgers, S
    Belderbos, J
    Klomp, H
    LUNG CANCER, 2005, 49 : S170 - S170
  • [30] Treatment of resectable stage IIIA non-small cell lung cancer
    Cardenal, Felipe
    Palmero, Ramon
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : 13 - 15
12345